Merck & Co., Inc. (NYSE:MRK) Shares Bought by Monte Financial Group LLC

Monte Financial Group LLC raised its position in shares of Merck & Co., Inc. (NYSE:MRK) by 13.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 50,159 shares of the company’s stock after buying an additional 5,994 shares during the quarter. Merck & Co., Inc. accounts for 3.1% of Monte Financial Group LLC’s portfolio, making the stock its 9th largest position. Monte Financial Group LLC’s holdings in Merck & Co., Inc. were worth $3,879,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of MRK. Toth Financial Advisory Corp purchased a new stake in shares of Merck & Co., Inc. in the second quarter worth approximately $32,000. CBIZ Investment Advisory Services LLC increased its holdings in Merck & Co., Inc. by 180.7% in the first quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the company’s stock worth $32,000 after buying an additional 271 shares during the last quarter. Lion Street Advisors LLC acquired a new position in Merck & Co., Inc. in the first quarter worth approximately $35,000. Lake Point Wealth Management increased its holdings in Merck & Co., Inc. by 159.0% in the first quarter. Lake Point Wealth Management now owns 518 shares of the company’s stock worth $40,000 after buying an additional 318 shares during the last quarter. Finally, Watson Rebecca acquired a new position in Merck & Co., Inc. in the second quarter worth approximately $48,000. 74.26% of the stock is owned by institutional investors.

MRK has been the topic of a number of research reports. SVB Leerink lowered their price target on Merck & Co., Inc. from $98.00 to $95.00 and set an “outperform” rating on the stock in a report on Wednesday, April 29th. Mizuho reiterated a “buy” rating and set a $100.00 price target on shares of Merck & Co., Inc. in a report on Friday, July 31st. UBS Group lowered their price target on Merck & Co., Inc. from $96.00 to $92.00 and set a “buy” rating on the stock in a report on Monday, April 13th. Goldman Sachs Group upgraded Merck & Co., Inc. from a “neutral” rating to a “buy” rating and increased their price target for the company from $91.00 to $105.00 in a report on Monday. Finally, Guggenheim lowered their price target on Merck & Co., Inc. from $101.00 to $93.00 and set a “buy” rating on the stock in a report on Wednesday, April 29th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have given a buy rating to the company’s stock. Merck & Co., Inc. currently has an average rating of “Buy” and a consensus price target of $94.93.

In related news, EVP Julie L. Gerberding sold 36,285 shares of the firm’s stock in a transaction on Friday, July 17th. The stock was sold at an average price of $80.00, for a total value of $2,902,800.00. Following the completion of the transaction, the executive vice president now directly owns 62,862 shares of the company’s stock, valued at $5,028,960. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.28% of the stock is owned by company insiders.

MRK stock traded down $0.59 during midday trading on Thursday, hitting $81.05. The stock had a trading volume of 6,923,089 shares, compared to its average volume of 11,592,609. The firm has a market capitalization of $204.89 billion, a price-to-earnings ratio of 19.78, a P/E/G ratio of 2.12 and a beta of 0.48. Merck & Co., Inc. has a 52 week low of $65.25 and a 52 week high of $92.64. The stock has a 50-day simple moving average of $78.15 and a 200 day simple moving average of $79.76. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 0.82.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Friday, July 31st. The company reported $1.37 EPS for the quarter, topping the consensus estimate of $1.14 by $0.23. The firm had revenue of $10.87 billion during the quarter, compared to analysts’ expectations of $10.52 billion. Merck & Co., Inc. had a return on equity of 53.61% and a net margin of 22.20%. Merck & Co., Inc.’s quarterly revenue was down 7.6% compared to the same quarter last year. During the same period last year, the business earned $1.30 earnings per share. On average, equities analysts forecast that Merck & Co., Inc. will post 5.72 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a $0.61 dividend. The ex-dividend date of this dividend is Monday, September 14th. This represents a $2.44 annualized dividend and a yield of 3.01%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 47.01%.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Further Reading: Stock Symbols and CUSIP Explained

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.